Harvard Management Company’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Harvard Management Company’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-326,029	Closed	-$1.25M	–	33
2023 Q2	$1.25M	Sell	326,029 -2,769	-0.8%	-$10.2K	0.12%	24
2023 Q1	$993K	Hold	328,798	–	–	0.1%	41
2022 Q4	$674K	Hold	328,798	–	–	0.08%	43
2022 Q3	$1.14M	Hold	328,798	–	–	0.14%	42
2022 Q2	$1.38M	Hold	328,798	–	–	0.16%	37
2022 Q1	$1M	Hold	328,798	–	–	0.1%	41
2021 Q4	$1.53M	Hold	328,798	–	–	0.14%	40
2021 Q3	$2.54M	Hold	328,798	–	–	0.15%	34
2021 Q2	$2.83M	Hold	328,798	–	–	0.16%	34
2021 Q1	$3.73M	Buy	+328,798	New	+$5.16M	0.21%	34

Other funds holding DBTX

ACA

Atlas Capital Advisors Jackson, Wyoming $875M AUM

Harvard Management Company's DBTX Position: Q3 2023 in Review

Harvard Management Company sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 326,029 shares — an estimated $1.25M sold.

Harvard Management Company first reported a position in DBTX in Q1 2021 and held it in 10 quarters. The position peaked at $3.73M in Q1 2021. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

Harvard Management Company reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Harvard Management Company sold 326,029 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.25M.
Harvard Management Company first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Harvard Management Company's Decibel Therapeutics, Inc. Common Stock position peaked at $3.73M in Q1 2021.
1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Harvard Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.